The Experts below are selected from a list of 1677 Experts worldwide ranked by ideXlab platform

Leszek Nogowski - One of the best experts on this subject based on the ideXlab platform.

  • Rapid Communications Effects of phytoestrogen-coumestrol on lipid and carbohydrate metabolism in young ovariectomized rats may be independent of its estrogenicity
    1999
    Co-Authors: Leszek Nogowski
    Abstract:

    Two groups of young ovariectomized female rats received one of two treatments. The first group was fed coumestrol in lab chow (200mg of coumestrol per day) for 14 days; the second group received coumestrol (40 mg/L) via perfusion medium. There was a significant increase (78% compared with the control group) in the uterine weight after coumestrol treatment, which supports the estrogen-like activity of coumestrol. Phytoestrogen diminished the liver and skeletal muscle glycogen contents by 18% and 29%, respectively, and increased the Blood glucose Level by 24%. Glycogenolytic activity of coumestrol was observed when it acted directly on the liver areas. Although phytoestrogen did not influence insulin and Glucagon Blood Level, liver and to some degree muscle susceptibility to insulin (measured as hormone binding by insulin receptors) was decreased. Coumestrol increased the content of triglycerides in muscle by 113% and enhanced the liver lipid synthesis from glucose by 179%. Liver cholesterol concentration was increased both after coumestrol feeding (by 12%) and when it acted directly on the liver (by 16%). These observations suggest that coumestrol is in general anabolic with regard to lipid and catabolic within-carbohydrate metabolism of young ovariectomized female rats. Based on the results of this study, it is concluded that influence of coumestrol on lipid and carbohydrate metabolism of ovariectomized rats is in part not related to its estrogenic action. (J. Nutr. Biochem. 10:664 ‐ 669, 1999) © Elsevier Science Inc. 1999. All rights reserved.

  • Effects of phytoestrogen-coumestrol on lipid and carbohydrate metabolism in young ovariectomized rats may be independent of its estrogenicity
    The Journal of nutritional biochemistry, 1999
    Co-Authors: Leszek Nogowski
    Abstract:

    Two groups of young ovariectomized female rats received one of two treatments. The first group was fed coumestrol in lab chow (200 μg of coumestrol per day) for 14 days; the second group received coumestrol (40 mg/L) via perfusion medium. There was a significant increase (78% compared with the control group) in the uterine weight after coumestrol treatment, which supports the estrogen-like activity of coumestrol. Phytoestrogen diminished the liver and skeletal muscle glycogen contents by 18% and 29%, respectively, and increased the Blood glucose Level by 24%. Glycogenolytic activity of coumestrol was observed when it acted directly on the liver areas. Although phytoestrogen did not influence insulin and Glucagon Blood Level, liver and to some degree muscle susceptibility to insulin (measured as hormone binding by insulin receptors) was decreased. Coumestrol increased the content of triglycerides in muscle by 113% and enhanced the liver lipid synthesis from glucose by 179%. Liver cholesterol concentration was increased both after coumestrol feeding (by 12%) and when it acted directly on the liver (by 16%). These observations suggest that coumestrol is in general anabolic with regard to lipid and catabolic within-carbohydrate metabolism of young ovariectomized female rats. Based on the results of this study, it is concluded that influence of coumestrol on lipid and carbohydrate metabolism of ovariectomized rats is in part not related to its estrogenic action.

  • Effect of phytooestrogen--coumestrol and oestrone on some aspects of carbohydrate metabolism in ovariectomized female rats.
    Archivum veterinarium Polonicum, 1992
    Co-Authors: Leszek Nogowski, Krzysztof W. Nowak, Paweł Maćkowiak
    Abstract:

    The purpose of the presented study is a comparison of phytooestrogen--coumestrol and oestrone effects on carbohydrate metabolism in ovariectomized female rats and to examine the participation of pancreatic hormones in changes of this metabolism. Administration of coumestrol diminished muscle glycogen in investigated animals. There were no significant changes in insulin and Glucagon Blood Level but decrease in the specific insulin binding in the muscle membranes was observed. It suggests that coumestrol effects the insulin receptor activity in this tissue and it could be a cause of glycogen deficiency.

Agnieszka Ziolkowska - One of the best experts on this subject based on the ideXlab platform.

  • Effects of prolonged exendin-4 administration on entero-insular axis of normal and streptozotocin-induced diabetic rats.
    International journal of molecular medicine, 2003
    Co-Authors: Ludwik K. Malendowicz, Krzysztof W. Nowak, Carlo Macchi, Gastone G. Nussdorfer, Agnieszka Zyterska, Agnieszka Ziolkowska
    Abstract:

    The effects of the Glucagon-like peptide 1 (GLP-1) receptor agonist exendin-4 (EX4) and antagonist EX4(9-39) EX4-A on entero-insular axis have been investigated in normoglycemic and streptozotocin (STZ)-induced diabetic rats. Rats were administered daily subcutaneous injections of 1 nmol/kg EX4 and/or EX4-A for 7 days, and were decapitated 3 h after the last injection. In STZ-untreated rats, EX4 reduced body-weight (BW) gain and raised glycemia, and the effects were prevented by EX4-A; conversely, EX4 did not alter plasma concentrations of insulin, Glucagon and leptin. STZ-treated rats displayed body and hematochemical alterations typical of experimental diabetes: decrease in BW and insulin Blood Level, coupled with normal Glucagon plasma concentration and marked hyperglycemia. In diabetic rats, both EX4 and EX4-A decreased BW gain, thereby suggesting a mechanism at least in part independent of GLP- I receptors. EX4 did not alter Glucagon Blood Level, but decreased glycemia and raised insulin and leptin plasma Levels. These effects were annulled by EX4-A, which indicates that they occur through the activation of GLP-1 receptors. Collectively, our findings add support to the view that EX4 can be considered an important therapeutical tool to improve glucose metabolism in diabetes.

Krzysztof W. Nowak - One of the best experts on this subject based on the ideXlab platform.

  • Effects of prolonged exendin-4 administration on entero-insular axis of normal and streptozotocin-induced diabetic rats.
    International journal of molecular medicine, 2003
    Co-Authors: Ludwik K. Malendowicz, Krzysztof W. Nowak, Carlo Macchi, Gastone G. Nussdorfer, Agnieszka Zyterska, Agnieszka Ziolkowska
    Abstract:

    The effects of the Glucagon-like peptide 1 (GLP-1) receptor agonist exendin-4 (EX4) and antagonist EX4(9-39) EX4-A on entero-insular axis have been investigated in normoglycemic and streptozotocin (STZ)-induced diabetic rats. Rats were administered daily subcutaneous injections of 1 nmol/kg EX4 and/or EX4-A for 7 days, and were decapitated 3 h after the last injection. In STZ-untreated rats, EX4 reduced body-weight (BW) gain and raised glycemia, and the effects were prevented by EX4-A; conversely, EX4 did not alter plasma concentrations of insulin, Glucagon and leptin. STZ-treated rats displayed body and hematochemical alterations typical of experimental diabetes: decrease in BW and insulin Blood Level, coupled with normal Glucagon plasma concentration and marked hyperglycemia. In diabetic rats, both EX4 and EX4-A decreased BW gain, thereby suggesting a mechanism at least in part independent of GLP- I receptors. EX4 did not alter Glucagon Blood Level, but decreased glycemia and raised insulin and leptin plasma Levels. These effects were annulled by EX4-A, which indicates that they occur through the activation of GLP-1 receptors. Collectively, our findings add support to the view that EX4 can be considered an important therapeutical tool to improve glucose metabolism in diabetes.

  • Effect of phytooestrogen--coumestrol and oestrone on some aspects of carbohydrate metabolism in ovariectomized female rats.
    Archivum veterinarium Polonicum, 1992
    Co-Authors: Leszek Nogowski, Krzysztof W. Nowak, Paweł Maćkowiak
    Abstract:

    The purpose of the presented study is a comparison of phytooestrogen--coumestrol and oestrone effects on carbohydrate metabolism in ovariectomized female rats and to examine the participation of pancreatic hormones in changes of this metabolism. Administration of coumestrol diminished muscle glycogen in investigated animals. There were no significant changes in insulin and Glucagon Blood Level but decrease in the specific insulin binding in the muscle membranes was observed. It suggests that coumestrol effects the insulin receptor activity in this tissue and it could be a cause of glycogen deficiency.

Ludwik K. Malendowicz - One of the best experts on this subject based on the ideXlab platform.

  • Effects of prolonged exendin-4 administration on entero-insular axis of normal and streptozotocin-induced diabetic rats.
    International journal of molecular medicine, 2003
    Co-Authors: Ludwik K. Malendowicz, Krzysztof W. Nowak, Carlo Macchi, Gastone G. Nussdorfer, Agnieszka Zyterska, Agnieszka Ziolkowska
    Abstract:

    The effects of the Glucagon-like peptide 1 (GLP-1) receptor agonist exendin-4 (EX4) and antagonist EX4(9-39) EX4-A on entero-insular axis have been investigated in normoglycemic and streptozotocin (STZ)-induced diabetic rats. Rats were administered daily subcutaneous injections of 1 nmol/kg EX4 and/or EX4-A for 7 days, and were decapitated 3 h after the last injection. In STZ-untreated rats, EX4 reduced body-weight (BW) gain and raised glycemia, and the effects were prevented by EX4-A; conversely, EX4 did not alter plasma concentrations of insulin, Glucagon and leptin. STZ-treated rats displayed body and hematochemical alterations typical of experimental diabetes: decrease in BW and insulin Blood Level, coupled with normal Glucagon plasma concentration and marked hyperglycemia. In diabetic rats, both EX4 and EX4-A decreased BW gain, thereby suggesting a mechanism at least in part independent of GLP- I receptors. EX4 did not alter Glucagon Blood Level, but decreased glycemia and raised insulin and leptin plasma Levels. These effects were annulled by EX4-A, which indicates that they occur through the activation of GLP-1 receptors. Collectively, our findings add support to the view that EX4 can be considered an important therapeutical tool to improve glucose metabolism in diabetes.

Carlo Macchi - One of the best experts on this subject based on the ideXlab platform.

  • Effects of prolonged exendin-4 administration on entero-insular axis of normal and streptozotocin-induced diabetic rats.
    International journal of molecular medicine, 2003
    Co-Authors: Ludwik K. Malendowicz, Krzysztof W. Nowak, Carlo Macchi, Gastone G. Nussdorfer, Agnieszka Zyterska, Agnieszka Ziolkowska
    Abstract:

    The effects of the Glucagon-like peptide 1 (GLP-1) receptor agonist exendin-4 (EX4) and antagonist EX4(9-39) EX4-A on entero-insular axis have been investigated in normoglycemic and streptozotocin (STZ)-induced diabetic rats. Rats were administered daily subcutaneous injections of 1 nmol/kg EX4 and/or EX4-A for 7 days, and were decapitated 3 h after the last injection. In STZ-untreated rats, EX4 reduced body-weight (BW) gain and raised glycemia, and the effects were prevented by EX4-A; conversely, EX4 did not alter plasma concentrations of insulin, Glucagon and leptin. STZ-treated rats displayed body and hematochemical alterations typical of experimental diabetes: decrease in BW and insulin Blood Level, coupled with normal Glucagon plasma concentration and marked hyperglycemia. In diabetic rats, both EX4 and EX4-A decreased BW gain, thereby suggesting a mechanism at least in part independent of GLP- I receptors. EX4 did not alter Glucagon Blood Level, but decreased glycemia and raised insulin and leptin plasma Levels. These effects were annulled by EX4-A, which indicates that they occur through the activation of GLP-1 receptors. Collectively, our findings add support to the view that EX4 can be considered an important therapeutical tool to improve glucose metabolism in diabetes.